Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NEXL -- Ignore unavailable to you. Want to Upgrade?

To: SIer formerly known as Joe B. who wrote (1237)	12/17/1997 11:11:00 AM
From: R Hamilton	Read Replies (1) \| Respond to of 1704

Looking back into the vmrx archives.....thought this post might generate some comments and perhaps we could get Laura to update us on the status of some of these items: \| Next \| Respond \| Earnings \| To: philip TESORIERO (1083 ) From: arnold silver Wednesday, Aug 20 1997 11:59AM EST Reply # of 1237 OK Phil here it is, Responses Date: 97-08-20 10:12:04 EDT From: lam@vimrx.com (Laura) To: Arnie70@aol.com ('Arnie70@aol.com') Hello Arnie. Answers to the questions follow. Sorry for the two day delay, I have been traveling. Q: Are they looking to build the pipeline? more acquisitions? A: For the next few months, we are focused on finalizing the VIMRX/Baxter new cell therapy company and aggressively developing our existing pipeline. But, if something interesting comes up, we will be opportunistic. Especially in our target areas of cell therapies, gene research and therapeutics for cancer and viral diseases. We love doing deals! Q:Intensify research on the existing potentials? A: Yes, the programs in the VIMRX pipeline are moving forward very quickly. We will file an IND with the FDA on VM201 in early 1998. VM301 is going to be going into humans within weeks and I will announce it at that time. We will be making some go/no go decisions on the hypericin program based on the results of the five studies we unblind in the 4Q. We will fund all of the programs with the highest potential and positive results. In VIMRX Genomics Inc., you will see a few scientific announcements in the near term. If you add in the Baxter events, there are a number of positive research announcements coming out of our pipeline in the near future. Q:Create some new affiliations? A: Our business development efforts are focused on securing pharmaceutical/biotechnology partners to generate revenues. (We will also consider affiliations for the new cell therapies business to help us to expand research into other areas outside of cancer.) Innovir provides many opportunities for industry collaboration and we will announce any partnerships as they are finalized. Bill McIntosh, our new head of business development, is excellent and has years of pharmaceutical experience. Q: Acquire a company w/positive cash flow. A: Always a possibility I assume. Keep in mind that the Baxter/VIMRX new company will provide revenues immediately and in time will be positive. We are still expecting FDA approval of the Isolex system this year. Q: How is the Baxter deal going ,and when will it be final ? A: Everything is going very well! Agreements are scheduled to be signed in September. Then, we need to send a proxy to request shareholder and board approval. We are very excited about the formation of this company and its potential. Q: It was mentioned on the conference call, you will be concentrating on shareholder value in the next month .What do you have scheduled ? A: Our focus is always on shareholder value - every month! We are very pleased with the efforts made to reshape this company and create new prospects for growth. We are well positioned to quickly develop technologies with significant commercial potential. We are also ready to deliver income from a number of multiple products and collaborations. On the IR front, we are committed to 5-10 institutional/analyst meetings per month. We are selling our story very aggressively. So far, the meetings have been very positive and our management team well received. Research reports are being considered. Many institutions have told us to try to be patient and focus on finalizing the new company and moving our clinical programs forward. We agree, but understand how patient our shareholders have been waiting for a consistent positive move in the stock. We are focusing on the programs that will best provide that value to you. Go VIMRX! Thank you and your board participants for your support. PS (Please encourage your fellow investors to ask questions directly on the conference call. Dick and Dave can discuss many of these issues directly and they can continue to increase your confidence on the company's longer term potential.) looks pretty good to me, Arnie<<<<<<<<<<<<<<<<<<<< status VM301?,,,,innovir major pharm alliance???VM201 ind on schedule?????? or has the baxter fiasco put everything on hold...what if isolex doesn't get approved. where is our revenue source? rhonda